Q-omics provides the consensus-scored TPM3P9 profile across patient tissues and cancer cell-line models. TPM3P9 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TPM3P9 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, TPM3P9 RNA expression shows 18,475 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BLCA as cancer lineages where TPM3P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPM3P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPM3P9 survival associations across molecular data types. TPM3P9 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPM3P9 RNA expression–survival associations across cancer types. High TPM3P9 expression shows unfavorable associations in ACC, LGG, LUSC, KIRP and LIHC, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TPM3P9 RNA expression.
This table summarizes TPM3P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for TPM3P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPM3P9 shows lower tumor expression in THCA and higher tumor expression in BLCA, STAD, COAD, KIRC and LIHC. The BLCA box plot shows higher TPM3P9 RNA expression in tumor versus normal tissue (log2 FC = +1.189, t-test p < 0.001).
This table shows molecular features associated with TPM3P9 in patient tissues and cancer cell lines. In patient samples, TPM3P9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TPM3P9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
